US drugmaker Mallinckrodt (NYSE: MNK) has entered into an agreement to acquire Ikaria, a privately-held critical care company, from a Madison Dearborn-led investor group in a transaction valued at around $2.3 billion.
Madison Dearborn bought Ikaria for around $1.6 billion early last year (The Pharma Letter January 3, 2014).
Subject to customary closing conditions, the companies expect the transaction to be completed early in the second calendar quarter of 2015, Mallinckrodt's third fiscal quarter. Assuming this timing, the transaction is expected to add at least $150 million in net sales and be accretive to Mallinckrodt's fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share. Mallinckrodt’s shares were up 5% at $122 in pre-market trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze